India’s vaccine development efforts have got a further fillip with the first mRNA-based Covid-19 vaccine candidate HGCO19, being developed by Pune-based Emcure Pharmaceuticals' subsidiary Gennova Biopharmaceuticals, entering into the next stage of clinical trials.

A few days ago, India had approved the world's first plasmid DNA vaccine, ZycoV-D from Zydus Cadila. The Drug Controller General of India yesterday approved Phase II and Phase III study protocols for HGCO19, following the Vaccine Subject Expert Committee (SEC) reviewed the interim Phase I data, and found that HGCO19 was safe, tolerable, and immunogenic in the participants of the study. The next stage trial is to commence in early September.
https://www.businesstoday.in/industry/pharma/story/indias-first-mrn...